GV has contributed to a $92m series B for Tenaya, three years after it was spun out of Gladstone Institutes and University of Texas Southwestern Medical Center.
Tenaya Therapeutics, a US-based developer of treatments for heart disease based on research at Gladstone Institutes and University of Texas Southwestern Medical Center, yesterday raised $92m in a series B round led by Casdin Capital.
GV, an early-stage corporate venturing subsidiary of technology conglomerate Alphabet, also took part in the round, as did Column Group and a range of undisclosed new and existing shareholders.
Founded in 2016, Tenaya is working on drugs that address the underlying causes of heart disease. Its approach relies on three separate platforms: Cellular Regeneration, Gene Therapy and Precision Medicine.
Cellular Regeneration uses adeno-associated virus (AAV) vectors to restore cardiac function, while Gene Therapy relies on AAV vectors to deliver payloads to specific cells in the heart, and Precision Medicine identifies and validates targets for treatments.
The series B funding will allow Tenaya to advance its pipeline and further develop its technology, capabilities and intellectual property underlying its three platforms.
Anthony Philippakis, venture partner at GV, will join the board as an observer, and Eli Casdin, chief investment officer at Casdin Capital, will join the board of directors.
Tenaya previously received $50m in series A capital from Column Group in 2016.